The Thioaptamer Diagnostic System will be commercialized first in the research support market, and then later as an FDA-approved hand-held clinical diagnostic system for non-traditional and resource poor locations. Clinical TDS units will be targeted for use in physician offices and by emergency responders. Research support market units will be targeted at lower-throughput biomedical research laboratories in universities and companies with limited capital budgets that have limited or no access to core support laboratories.
Successful development of this system will provide NASA with both near-term as well as long-term advantages. Near-term, a non-clinical version of the system will be extraordinarily useful for conducting research on ISS into human adaptation to microgravity. The TDS could monitor levels of numerous biomarkers in astronauts on orbit and would eliminate the need to freeze samples on orbit and return them to Earth for ground-based testing. Long-term, the clinical version of the TDS will provide a robust, flight tested diagnostic capability for missions to the moon and Mars. Virtually any type of ambient stable assay that is of interest to NASA could be developed for the system.
More »